Abstract
This study was a randomized controlled trial of 6 months of oral acetretin, 30 mg per day, in 44 kidney transplant recipients in The Netherlands. All subjects had 10 or more keratotic skin lesions on the hands and forearms at the outset. Among the 19 subjects in the experimental group for whom information was available from at least one follow-up visit, nine had new nonmelanoma skin cancers (16 squamous cell carcinomas, 2 basal cell carcinomas). This finding was significantly higher than the two squamons cell carcinomas (one in each of two subjects) diagnosed among the 19 placebo recipients who were able to be examined. Among those with a history of skin cancers, 7 of 10 in the placebo group and one of nine in the acetretin group had an additional skin cancer in the 6-month study period. After discontinuation of acetretin at the end of the trial, the acetrefin group had skin cancers at a rate similar to that of the placebo group during the Irial. Although the expected retinoid side effects occunexi in the acetretin-treated patients, no difficulties were noted with the transplanted kidneys.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
